Evaluation of HER-2/neu status by real-time quantitative PCR in malignant cartilaginous tumors.
The expression of HER-2/neu has been proposed to be a prognostic indicator in osteosarcoma. To clarify the actual frequency of HER-2/neu expression in primary malignant cartilaginous tumors, we examined 89 cases comprising 17 conventional chondrosarcomas, 33 mesenchymal chondrosarcomas, and 39 clear cell chondrosarcomas. We used real-time PCR (LightCycler) assay to quantify the HER-2/neu gene status. The crossing point of HER-2 in normal control bone was 27.77. The crossing points of HER-2 in conventional, mesenchymal, and clear cell chondrosarcomas were 28.48+/-1.79, 27.74+/-3.02, 28.57+/-1.54, respectively. In conclusion, the amplification and overexpression of the HER-2/neu oncogene is absent or at least very rare in malignant cartilaginous tumors. The level of expression of HER-2/neu was similar in all cartilaginous tumor types.
Park
Hye-Rim
HR
Department of Pathology, Hallym University, Anyang, Korea.
Kim
Youn-Wha
YW
Jung
Woon Won
WW
Kim
Hyun Sook
HS
Unni
K K
KK
Park
Yong-Koo
YK
D002813:Chondrosarcoma / Q000378:metabolism*; D018211:Chondrosarcoma, Mesenchymal / Q000378:metabolism*; D004247:DNA / Q000378:metabolism; D017931:DNA Primers / Q000494:pharmacology; D018734:Genes, erbB-2 / Q000235:genetics; D006801:Humans; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018227:Sarcoma, Clear Cell / Q000378:metabolism*
D004247:DNA; D017931:DNA Primers; D018719:Erb-b2 Receptor Tyrosine Kinases